Unknown

Dataset Information

0

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.


ABSTRACT: The AIDS Clinical Trials Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficiency virus (HIV) regimens in Africa and Asia.Eligible subjects had received first-line regimens for at least 6 months and had plasma HIV-1 RNA levels 1000-200 000 copies/mL. All subjects received LPV/r 400/100 mg twice daily. VF was defined as failure to suppress to <400 copies/mL by week 24, or confirmed rebound to >400 copies/mL at or after week 16 following confirmed suppression. Subjects with VF added emtricitabine 200 mg/tenofovir 300 mg (FTC/TDF) once daily. The probability of continued HIV-1 RNA <400 copies/mL on LPV/r monotherapy through week 104 was estimated with a 95% confidence interval (CI); predictors of treatment success were evaluated with Cox proportional hazards models.One hundred twenty-three subjects were enrolled. Four subjects died and 2 discontinued prematurely; 117 of 123 (95%) completed 104 weeks. Through week 104, 49 subjects met the primary endpoint; 47 had VF, and 2 intensified treatment without VF. Of the 47 subjects with VF, 41 (33%) intensified treatment, and 39 of 41 subsequently achieved levels <400 copies/mL. The probability of continued suppression <400 copies/mL over 104 weeks on LPV/r monotherapy was 60% (95% CI, 50%-68%); 80%-85% maintained levels <400 copies/mL with FTC/TDF intensification as needed. Ultrasensitive assays on specimens with HIV-1 RNA level <400 copies/mL at weeks 24, 48, and 104 revealed that 61%, 62%, and 65% were suppressed to <40 copies/mL, respectively.LPV/r monotherapy after first-line VF with FTC/TDF intensification when needed provides durable suppression of HIV-1 RNA over 104 weeks.NCT00357552.

SUBMITTER: Kumarasamy N 

PROVIDER: S-EPMC4425828 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

Kumarasamy Nagalingeswaran N   Aga Evgenia E   Ribaudo Heather J HJ   Wallis Carole L CL   Katzenstein David A DA   Stevens Wendy S WS   Norton Michael R MR   Klingman Karin L KL   Hosseinipour Mina C MC   Crump John A JA   Supparatpinyo Khuanchai K   Badal-Faesen Sharlaa S   Bartlett John A JA  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20150218 10


<h4>Background</h4>The AIDS Clinical Trials Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficiency virus (HIV) regimens in Africa and Asia.<h4>Methods</h4>Eligible subjects had received first-line regimens for at least 6 months and had plasma HIV-1 RNA levels 1000-200 000 copies/mL. All subjects received LPV/r 400/100 mg twice daily. VF was defined as failure to suppress to <400 copies/mL by week 24, or con  ...[more]

Similar Datasets

| S-EPMC4004638 | biostudies-literature
| S-EPMC5047431 | biostudies-literature
| S-EPMC5305227 | biostudies-literature
| S-EPMC4228778 | biostudies-literature
| S-EPMC4267506 | biostudies-literature
| S-EPMC6861410 | biostudies-literature
| S-EPMC4352713 | biostudies-literature
| S-EPMC5106322 | biostudies-literature
| S-EPMC4867099 | biostudies-literature
| S-EPMC4728832 | biostudies-literature